Ascendis: Recommended Phase 2 Dose, Cohort Expansion for Phase 1/2 Trial of TransCon TLR7/8 Agonist in Solid Tumors

  TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical activity as monotherapy or in combination with pembrolizumab

- Abstract for dose-escalation topline data accepted for an oral presentation at SITC 2022, November 8-12 in Boston

- Recommended Phase 2 dose to be evaluated in four indication-specific dose-expansion cohorts

https://www.biospace.com/article/releases/ascendis-pharma-announces-recommended-phase-2-dose-and-cohort-expansion-for-transcendit-101-a-phase-1-2-clinical-trial-of-transcon-tlr7-8-agonist-in-solid-tumors/